Overview

PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma

Status:
Terminated
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Given the growing importance of anti-angiogenic therapies in the treatment of metastatic renal carcinoma, it is expected that this trial will establish the preliminary data needed to apply for funding of a larger clinical investigation of the potential role of PET perfusion imaging in management of renal carcinoma, and potentially other cancers.
Phase:
N/A
Details
Lead Sponsor:
Indiana University
James Fletcher
Treatments:
Sunitinib